204 related articles for article (PubMed ID: 32123305)
21. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
Jia M; Liao N; Chen B; Zhang G; Wang Y; Li X; Cao L; Mok H; Ren C; Li K; Li C; Wen L; Lin J; Wei G; Balch CM
Breast Cancer; 2021 May; 28(3):644-652. PubMed ID: 33386585
[TBL] [Abstract][Full Text] [Related]
22. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.
Gasch C; Oldopp T; Mauermann O; Gorges TM; Andreas A; Coith C; Müller V; Fehm T; Janni W; Pantel K; Riethdorf S
Mol Oncol; 2016 Oct; 10(8):1330-43. PubMed ID: 27491860
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
24. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
25. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
28. Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?
Laé M; Lebel A; Hamel-Viard F; Asselain B; Trassard M; Sastre X; Kirova YM
Cancer Radiother; 2015 May; 19(3):168-74. PubMed ID: 25863565
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
30. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
34. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
35. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA mutations matter for cancer in dogs.
Kim JH
Res Vet Sci; 2020 Dec; 133():39-41. PubMed ID: 32932196
[TBL] [Abstract][Full Text] [Related]
37. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
38. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
39. Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Lian J; Xu EW; Xi YF; Wang HW; Bu P; Wang JF; Wang LX
Technol Cancer Res Treat; 2020; 19():1533033820950832. PubMed ID: 33047659
[TBL] [Abstract][Full Text] [Related]
40. Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of a Simplified 2-tier Grading System.
Kuba MG; Dermawan JK; Xu B; Singer S; Plitas G; Tap WD; D'Angelo SP; Rosenbaum E; Brogi E; Antonescu CR
Am J Surg Pathol; 2023 Mar; 47(3):307-317. PubMed ID: 36376999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
